Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957)
NCT05161598 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2025-12-16
Summary
Teclistamab pre-approval access in relapsed or refractory multiple myeloma.
Conditions
Interventions
- DRUG
-
Teclistamab will be administered subcutaneously (SC).
Sponsors & Collaborators
-
Janssen Research & Development, LLC
lead INDUSTRY
Principal Investigators
-
Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma
NCT07030517 ·Status: RECRUITING ·Phase: PHASE4
-
A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
NCT05338775 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma
NCT05849610 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
NCT06285318 ·Status: RECRUITING
-
Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)
NCT05238311 ·Status: NO_LONGER_AVAILABLE
-
Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
NCT03145181 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)
NCT06100237 ·Status: RECRUITING ·Phase: PHASE2
-
Limited-duration Teclistamab
NCT05932680 ·Status: RECRUITING ·Phase: PHASE2
-
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study on the Clinical Efficacy of Teclistamab
NCT06477783 ·Status: RECRUITING
-
Plan Development for Giving Teclistamab in the Outpatient Setting
NCT06251076 ·Status: RECRUITING ·Phase: PHASE4
-
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04586426 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
NCT07105059 ·Status: RECRUITING ·Phase: PHASE1
-
A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT06425991 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
NCT05972135 ·Status: RECRUITING ·Phase: PHASE2
-
A Safety Study of SGN-CD48A in Patients With Multiple Myeloma
NCT03379584 ·Status: TERMINATED ·Phase: PHASE1
-
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
NCT07075185 ·Status: RECRUITING ·Phase: PHASE1
-
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma
NCT03837509 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT04776018 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04634552 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy
NCT06066346 ·Status: RECRUITING ·Phase: PHASE2
-
Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma
NCT06183489 ·Status: RECRUITING ·Phase: PHASE2
-
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
NCT06993675 ·Status: RECRUITING ·Phase: PHASE2
-
Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma
NCT06880601 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma
NCT05572229 ·Status: RECRUITING ·Phase: PHASE2